Cited by

• Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options.

  Koleva-Kolarova R, Buchanan J, Vellekoop H, Huygens S, Versteegh M, Mölken MR, Szilberhorn L, Zelei T, Nagy B, Wordsworth S, Tsiachristas A; HEcoPerMed Consortium. Koleva-Kolarova R, et al. Appl Health Econ Health Policy. 2022 Jul;20(4):501-524. doi: 10.1007/s40258-021-00714-9. Epub 2022 Apr 4. Appl Health Econ Health Policy. 2022. PMID: 35368231 Free PMC article.
• Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma.

  Brammer JE, Braunstein Z, Katapadi A, Porter K, Biersmith M, Guha A, Vasu S, Yildiz VO, Smith SA, Buck B, Haddad D, Gumina R, William BM, Penza S, Saad A, Denlinger N, Vallakati A, Baliga R, Benza R, Binkley P, Wei L, Mocarski M, Devine SM, Jaglowski S, Addison D. Brammer JE, et al. J Immunother Cancer. 2021 Aug;9(8):e002303. doi: 10.1136/jitc-2020-002303. J Immunother Cancer. 2021. PMID: 34429331 Free PMC article.
• Spending For Orphan Indications Among Top-Selling Orphan Drugs Approved To Treat Common Diseases.

  Chua KP, Kimmel LE, Conti RM. Chua KP, et al. Health Aff (Millwood). 2021 Mar;40(3):453-460. doi: 10.1377/hlthaff.2020.01442. Health Aff (Millwood). 2021. PMID: 33646878 Free PMC article.
• Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States.

  Sathyanarayanan V, Flowers CR, Iyer SP. Sathyanarayanan V, et al. JCO Glob Oncol. 2020 Jul;6:1124-1133. doi: 10.1200/GO.20.00012. JCO Glob Oncol. 2020. PMID: 32692628 Free PMC article. Review.
• Cost-effectiveness of Tisagenlecleucel vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada.

  Furzer J, Gupta S, Nathan PC, Schechter T, Pole JD, Krueger J, Pechlivanoglou P. Furzer J, et al. JAMA Oncol. 2020 Mar 1;6(3):393-401. doi: 10.1001/jamaoncol.2019.5909. JAMA Oncol. 2020. PMID: 31971547 Free PMC article.